Company News
At iOmx, we’re committed to advancing science and sharing our journey along the way. In this section, you’ll find news, scientific publications, and key company updates that reflect our work, progress, and impact in the field of immuno-oncology.
Categories
iOmx Therapeutics
iOmx Therapeutics Receives Regulatory Approval of Clinical Trial Application for IOMX-0675
April 15, 2025
iOmx Therapeutics Receives Regulatory Approval of Clinical Trial Application for IOMX-0675
iOmx Therapeutics
iOmx Therapeutics submits Clinical Trial Application for IOMX-0675
December 19, 2024
iOmx Therapeutics submits Clinical Trial Application for IOMX-0675
iOmx Therapeutics
iOmx Therapeutics Initiates Phase Ib with OMX-0407
August 22, 2024
iOmx Therapeutics Initiates Phase Ib with OMX-0407
iOmx Therapeutics
iOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer
June 27, 2024
iOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer
iOmx Therapeutics
iOmx to present new data on lead programs and I/O target screening platform at AACR 2024
April 3, 2024
iOmx to present new data on lead programs and I/O target screening platform at AACR 2024
iOmx Therapeutics
iOmx Therapeutics attends upcoming scientific and industry conferences
November 1, 2023
iOmx Therapeutics attends upcoming scientific and industry conferences
iOmx Therapeutics
OMX 0407 : A novel spectrum selective small molecule kinase inhibitor in advanced/metastatic solid tumors
May 30, 2025
OMX 0407 : A novel spectrum selective small molecule kinase inhibitor in advanced/metastatic solid tumors
iOmx Therapeutics
IOMX-0235, a CCR9+ Cell Depleting Antibody for the Treatment of IBD with Best-in-Class Potential
May 13, 2025
IOMX-0235, a CCR9+ Cell Depleting Antibody for the Treatment of IBD with Best-in-Class Potential
iOmx Therapeutics
IOMX-0675, a LILRB1 / LILRB2 Cross-Specific Antibody That Repolarizes the Tumor Microenvironment to Drive Potent Anti-Tumor Activity
April 25, 2025
IOMX-0675, a LILRB1 / LILRB2 Cross-Specific Antibody That Repolarizes the Tumor Microenvironment to Drive Potent Anti-Tumor Activity
iOmx Therapeutics
OMX-0407 – a spectrum selective kinase inhibitor shows preclinical efficacy in RCC as well as Sarcomas
April 25, 2025
OMX-0407 – a spectrum selective kinase inhibitor shows preclinical efficacy in RCC as well as Sarcomas
iOmx Therapeutics
Pharmacodynamic biomarker modulation by OMX-0407, a novel, spectrum-selective kinase inhibitor for the treatment of angiosarcoma and renal cell carcinoma
April 25, 2025
Pharmacodynamic biomarker modulation by OMX-0407, a novel, spectrum-selective kinase inhibitor for the treatment of angiosarcoma and renal cell carcinoma
iOmx Therapeutics
IOMX-0675, a LILRB1/ LILRB2 cross-specific antibody that reprograms the tumor microenvironment to trigger potent anti-tumor activity
April 3, 2025